Q2 Earnings Forecast for Innoviva Issued By HC Wainwright

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Innoviva in a research note issued on Monday, July 14th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings of $0.57 per share for the quarter. HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva's Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.82 EPS, Q1 2026 earnings at $0.55 EPS, Q2 2026 earnings at $0.68 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $2.74 EPS.

INVA has been the topic of a number of other research reports. Wall Street Zen upgraded Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on Innoviva in a research note on Friday, July 11th. They issued an "overweight" rating and a $26.00 price objective on the stock.

Innoviva Price Performance

INVA stock traded down $0.18 during midday trading on Wednesday, reaching $19.71. 129,736 shares of the stock were exchanged, compared to its average volume of 711,998. The company has a fifty day moving average price of $19.89 and a 200 day moving average price of $18.64. Innoviva has a 52 week low of $16.67 and a 52 week high of $22.00. The stock has a market capitalization of $1.24 billion, a PE ratio of -19.50 and a beta of 0.37. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.48 and a quick ratio of 2.30.

Innoviva (NASDAQ:INVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter. The business had revenue of $88.63 million for the quarter. Innoviva had a positive return on equity of 15.77% and a negative net margin of 16.15%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Martingale Asset Management L P lifted its stake in shares of Innoviva by 0.7% in the 1st quarter. Martingale Asset Management L P now owns 78,412 shares of the biotechnology company's stock valued at $1,422,000 after purchasing an additional 570 shares during the period. BOKF NA raised its stake in Innoviva by 2.3% during the 4th quarter. BOKF NA now owns 28,648 shares of the biotechnology company's stock worth $495,000 after buying an additional 641 shares during the period. Farther Finance Advisors LLC raised its stake in Innoviva by 10.3% during the 1st quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company's stock worth $153,000 after buying an additional 795 shares during the period. Parallel Advisors LLC raised its stake in Innoviva by 157.5% during the 2nd quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company's stock worth $37,000 after buying an additional 1,131 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Innoviva by 3.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,490 shares of the biotechnology company's stock worth $546,000 after buying an additional 1,162 shares during the period. 99.12% of the stock is owned by institutional investors and hedge funds.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.